Licensing status

Publication and contact information

Infectious disease


DNA gyrase

In vitro and mouse studies identified thiazolopyridine urea DNA gyrase inhibitors that could be useful for treating tuberculosis. In Mycobacterium tuberculosis culture, thiazolopyridine urea-based compounds showed time- and concentration-dependent bactericidal activity. In a mouse model of M. tuberculosis infection, a lead member of the series caused dose-dependent decreases in lung bacterial counts compared with vehicle. Next steps could include optimizing and evaluating the lead inhibitor in additional models of M. tuberculosis infection.

SciBX 6(43); doi:10.1038/scibx.2013.1227
Published online Nov. 7, 2013

Patent and licensing status unavailable

Kale, M.G. et al. J. Med. Chem.; published online Oct. 3, 2013;
Contact: Sandeep R. Ghorpade, AstraZeneca India Pvt. Ltd.,
Bangalore, India